MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

246th out of 2,041 stocks

Pharmaceutical Preparations Industry

111th out of 769 stocks

3.4 Analyst's Opinion

Consensus Rating
MEI Pharma has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.60, MEI Pharma has a forecasted upside of 219.3% from its current price of $3.32.
Amount of Analyst Coverage
MEI Pharma has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
MEI Pharma has received 352 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MEI Pharma has received 284 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MEI Pharma has received 55.35% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote “Outperform” if you believe MEIP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MEI Pharma does not currently pay a dividend.
Dividend Growth
MEI Pharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MEI Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,750.00 in company stock.
Percentage Held by Insiders
Only 4.42% of the stock of MEI Pharma is held by insiders.
Percentage Held by Institutions
67.61% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for MEI Pharma are expected to grow in the coming year, from ($0.66) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MEI Pharma is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MEI Pharma is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MEI Pharma has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma or view top-rated stocks.

What stocks does MarketBeat like better than MEI Pharma?

Wall Street analysts have given MEI Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MEI Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.09. The firm had revenue of $1.24 million for the quarter, compared to the consensus estimate of $1.28 million. MEI Pharma had a negative trailing twelve-month return on equity of 33.55% and a negative net margin of 142.81%.
View MEI Pharma's earnings history.

How has MEI Pharma's stock been impacted by COVID-19?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEIP shares have increased by 114.2% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MEIP?

7 analysts have issued twelve-month target prices for MEI Pharma's shares. Their forecasts range from $9.00 to $13.00. On average, they anticipate MEI Pharma's share price to reach $10.60 in the next twelve months. This suggests a possible upside of 219.3% from the stock's current price.
View analysts' price targets for MEI Pharma or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:

Dr. Daniel P. Gold, Pres, CEO & Director (Age 67, Pay $1.14M)
Mr. Brian G. Drazba B.A., CPA, CPA, CFO & Sec. (Age 60, Pay $603k)
Mr. David M. Urso B.A., Esq., J.D., COO & Gen. Counsel (Age 57, Pay $718.75k)
Dr. Robert D. Mass, Chief Medical Officer (Age 67, Pay $294.59k)
Mr. David A. Walsey J.D., L.L.M., VP of IR & Corp. Communications
Mr. Brian T. Powl, Sr. VP of Marketing
Ms. Jamie A. Tereschuck, VP of HR
Dr. Ofir Moreno, Sr. VP of Pharmaceutical Sciences
Dr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 58)
Dr. Richard G. Ghalie, Sr. VP of Clinical Devel. (Age 63)

Who are some of MEI Pharma's key competitors?

Some companies that are related to MEI Pharma include Prelude Therapeutics (PRLD), Kronos Bio (KRON), Travere Therapeutics (TVTX), ImmunoGen (IMGN), Zymeworks (ZYME), DiaMedica Therapeutics (DMCAF), Zealand Pharma A/S (ZEAL), Shattuck Labs (STTK), Antibe Therapeutics (ATBPD), COMPASS Pathways (CMPS), Endo International (ENDP), Keros Therapeutics (KROS), Theravance Biopharma (TBPH), Y-mAbs Therapeutics (YMAB) and Aclaris Therapeutics (ACRS).
View all of MEIP's competitors.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (0.57%), Assenagon Asset Management S.A. (0.47%), EMC Capital Management (0.08%), The Manufacturers Life Insurance Company (0.06%), Commonwealth Equity Services LLC (0.04%) and Los Angeles Capital Management LLC (0.03%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma.

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company .
View insider buying and selling activity for MEI Pharma or view top insider-selling stocks.

Which major investors are buying MEI Pharma stock?

MEIP stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Commonwealth Equity Services LLC, Assenagon Asset Management S.A., EMC Capital Management, and Los Angeles Capital Management LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.32.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $373.59 million and generates $28.91 million in revenue each year. The company earns $-46,010,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MEI Pharma Stock Forecast, Price & News

Adding

Adding

Adding MEI Pharma, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About MEI Pharma

MarketRank™

Overall MarketRank™